Back to Search Start Over

Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis.

Authors :
Dammacco F
Lauletta G
Russi S
Leone P
Tucci M
Manno C
Monaco S
Ferrari S
Vacca A
Racanelli V
Source :
Clinical and experimental medicine [Clin Exp Med] 2019 Feb; Vol. 19 (1), pp. 1-21. Date of Electronic Publication: 2018 Nov 14.
Publication Year :
2019

Abstract

Cryoglobulins are circulating immunoglobulins that reversibly precipitate at temperatures below 37 °C. Type-II cryoglobulins consist of monoclonal IgM/polyclonal IgG immune complexes (ICs), whereas in type-III cryoglobulins both IgM and IgG are polyclonal. The clinical condition resulting from the presence of cryoglobulins in the blood is called mixed cryoglobulinemia (MC), which can be asymptomatic or manifest as cryoglobulinemic vasculitis (CV). Type-I cryoglobulins, consisting of a single monoclonal isotype, are detected in patients with lymphoproliferative disorders. It is now established that > 90% of MCs are associated with HCV infection. Clinically, the spectrum of symptoms may range in severity from occasional purpuric eruptions to life-threatening features. In addition to the development of liver cirrhosis and hepatocellular carcinoma, the possible progression of HCV-positive CV patients to B-cell non-Hodgkin lymphoma (B-NHL) has been reported. The pathogenetic role played by HCV infection in the onset of B-NHL is suggested by regression of the latter following the achievement of a sustained virologic response (SVR). For several years, interferon-α alone or combined with ribavirin has been the standard of care. However, the rates of clinical, biochemical, and virologic responses have been low, and the occurrence of relapse frequent. The addition of rituximab has resulted in a higher rate of responses. With the advent of direct-acting antiviral agents, SVR has been achieved in ~ 95% of CV patients. However, in a minority of patients, despite SVR, CV may persist or reappear over variable lengths of time from the completion of therapy. The eventual appearance of B-NHL is also possible.

Details

Language :
English
ISSN :
1591-9528
Volume :
19
Issue :
1
Database :
MEDLINE
Journal :
Clinical and experimental medicine
Publication Type :
Academic Journal
Accession number :
30430284
Full Text :
https://doi.org/10.1007/s10238-018-0536-z